Beta Drugs Ltd
Beta Drugs Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
From Beta Drugs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company aims to grow at a rate between 23%-30% annually across key segments.
- Domestic own branded business expected to continue 25%+ growth.
- CDMO business expected to grow 5%-10% annually.
- Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through.
- Dermatology (Derma) segment expected to grow from Rs. 12.3 crores to Rs. 30 crores next year and Rs. 45-50 crores in 3 years.
- Consolidated revenue guidance for FY26 is around Rs. 450 crores, with a vision to reach Rs. 750 crores by FY28.
- New product launches (e.g., NDDS, Oral Therapy) and expansions in regulated markets expected to fuel growth.
- Expected positive EBITDA in Dermatology from FY26 onwards.
- International markets, including Mexico, Brazil, Philippines, expected to contribute strong growth in coming years.
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
- Investment of approximately Rs. 11 crores has been made in facility upgrades, mainly in Adley Formulations and Adley Lab.
- The Company is actively looking for land or a plant for backward integration to manufacture intermediates, reducing dependency on China and ensuring a reliable supply chain for KSMs.
- R&D team has around 10 people currently, with ongoing investment in scientific and drug delivery system innovations.
- Potential strategic investments/M&A will be considered if good branded businesses become available, though there is nothing concrete on the table currently.
- Funds of around Rs. 117 crores raised remain largely parked in FDs, with selective utilization ongoing as opportunities arise.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The document does not explicitly mention the current or expected order book or pending orders in numeric terms.
- Rahul Batra mentions robust business operations with multiple strategic growth plans, indicating strong future demand.
- CDMO segment has about 30 clients, with 3 new clients added this year, suggesting ongoing and future order inflows.
- The company is actively preparing dossiers for regulatory approvals in multiple export markets (Mexico, Brazil, Thailand, Philippines, Vietnam), indicative of pending orders and potential new market entries.
- Transition to Mainboard and capital investments (e.g., new corporate office, API intermediate plant search) demonstrate readiness to handle increased order volumes.
- Management emphasizes a robust pipeline for the next 3-4 years and consistent growth of 23%-30% annually across segments, signifying a positive outlook on order inflow.
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Beta Drugs Ltd Q4 FY25 results?
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.